Aquestive Therapeutics (AQST) Q2 2023: License and Royalty Revenue Jumps 168% as Epinephrine Pipeline Advances
Aquestive Therapeutics’ Q2 marked a decisive pivot toward pipeline execution and royalty-driven growth, with sharp debt reduction and a 168% surge in license and royalty revenue reinforcing financial progress. Management’s confidence is anchored in advancing Anafilm’s pivotal trial and strategic out-licensing, positioning AQST for multi-year optionality as its non-device-based epinephrine asset nears critical milestones. With market expansion and regulatory catalysts ahead, investors should focus on the evolving mix shift and execution against clinical and partnership timelines.
Summary
- Royalty Model Expands: Out-licensing and manufacturing revenues now drive the majority of top-line growth.
- Pipeline Execution Accelerates: Anafilm pivotal trial protocol submitted, with FDA alignment expected near-term.
- Debt and Dilution Managed: Capital structure improved, supporting multi-year R&D runway and partnership flexibility.
Business Overview
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing orally administered therapies for central nervous system and allergy indications. The company’s business model is anchored in its proprietary PharmFilm technology, enabling sublingual and buccal drug delivery. Major segments include out-licensed products generating manufacturing, supply, and royalty revenue, and a pipeline led by Anafilm, an epinephrine sublingual film for anaphylaxis, and Libervant, a diazepam buccal film for seizure rescue. Legacy product Suboxone, an opioid dependence treatment, remains a significant near-term revenue contributor, while new pipeline assets and ex-US licensing offer future growth levers.
Performance Analysis
Aquestive’s second quarter results highlight a material shift toward a royalty and manufacturing-driven revenue base, as license and royalty revenue soared 168% year-over-year and manufacturing and supply revenue rose 18%, offsetting the wind-down of proprietary Simpazan sales. Excluding the prior year’s Simpazan sales, total revenue rose 24%, underscoring the strength of the out-licensing strategy. However, reported total revenue was flat due to the absence of legacy product sales, reflecting a deliberate move to a more capital-efficient model.
Cost discipline was evident, with net loss narrowing sharply on lower SG&A and R&D spend, and adjusted EBITDA loss improving meaningfully. Debt was reduced by nearly 25% year-over-year, and the company maintained a cash balance above $20 million for the third consecutive quarter, supported by warrant conversions and ATM facility usage. Gross margin variability was attributed to product mix and API sourcing dynamics, with management guiding for continued fluctuations as licensed product volumes ramp.
- License and Royalty Revenue Surges: 168% YoY increase signals success of out-licensing and non-dilutive capital strategy.
- SG&A and R&D Cost Cuts: Operating expenses fell, reflecting the pivot away from direct commercialization and focus on pipeline investment.
- Debt Reduction and Cash Preservation: Nearly 25% debt paid down, warrant overhang resolved, and cash runway extended via ATM and prudent spend.
Overall, the quarter reinforces a disciplined transition toward a leaner, IP-leveraged business model, with pipeline progress and partnership optionality now central to the investment case.
Executive Commentary
"We have a base business that generates revenue, is profitable and growing. We have two pipeline assets, anafilm epinephrine sublingual film and libervent diazepam buccal film, that have the potential to come to market in the next two to four years and be transformational to patients as the first and only oral rescue medications within their respective indications."
Dan Barber, Chief Executive Officer
"We reduced our outstanding debt by approximately 25% from $51.5 million on December 31st, 2022 to approximately $39 million on June 30th, 2023 through a combination of principal prepayments and scheduled principal amortization. We continue to manage expenses prudently with savings in research and development costs and expenses related to the out licensing of Simpizan and the elimination of our commercial infrastructure."
Ernie Toth, Chief Financial Officer
Strategic Positioning
1. Pipeline Progress: Anafilm and Libervant
Aquestive’s strategy centers on advancing Anafilm, a first-in-class sublingual epinephrine film for anaphylaxis, with the pivotal trial protocol now submitted to the FDA and a streamlined administration profile. Libervant’s NDA for the two-to-five-year-old age group targets an underserved pediatric segment, with management acknowledging regulatory and competitive risks but emphasizing the unmet need and orphan drug exclusivity nuances.
2. Out-Licensing and Royalty Leverage
Out-licensing is now the dominant revenue engine, with five licensed products driving manufacturing and royalty income. Ex-US partnership opportunities for Anafilm and Libervant in Europe and China are under active negotiation, offering future non-dilutive capital and geographic expansion.
3. Capital Structure and Cost Discipline
Debt reduction and cash preservation have been prioritized, with warrant overhang eliminated and the ATM facility providing liquidity. SG&A and R&D spend have been recalibrated, reflecting a shift from direct sales to pipeline investment, extending the cash runway to support near-term clinical milestones.
4. Market Expansion Tailwinds
Prescription growth in the epinephrine market is accelerating, with scripts trending up 20%+ year-over-year, driven by advocacy, legislative action, and heightened awareness. Management sees continued market expansion, which could amplify the commercial opportunity for Anafilm upon approval.
5. Optionality from Pipeline Assets
AQST 108, an epinephrine prodrug with a differentiated PK profile, is being evaluated for clinical advancement, potentially adding a third pillar to the pipeline. Management is balancing resource allocation to maximize value across current and future programs.
Key Considerations
This quarter’s results reflect a business in transition, with execution focused on pipeline advancement, capital efficiency, and leveraging intellectual property through partnerships. Investors should weigh the following:
Key Considerations:
- Pipeline Milestones Drive Value: Near-term FDA feedback and pivotal trial initiation for Anafilm are key inflection points.
- Royalty and Manufacturing Mix Shift: Out-licensing reduces risk and capital intensity, but future growth depends on pipeline success and partner execution.
- Cash Runway and Dilution Risk: ATM and warrant conversions bolster liquidity, but further pipeline investment may require additional capital if timelines extend.
- Market Expansion Can Amplify Upside: Epinephrine prescription growth and legislative changes could expand addressable markets for Anafilm and Libervant.
Risks
Regulatory risk remains high, with Anafilm and Libervant both subject to FDA review, potential orphan drug exclusivity disputes, and competitive interference. Revenue concentration in a small number of licensed products and reliance on partner execution introduce commercial risk. Gross margin variability due to product mix and API sourcing could pressure profitability. Capital needs may re-emerge if clinical or regulatory timelines slip, despite recent debt reduction and cash preservation.
Forward Outlook
For the third quarter, Aquestive guided to:
- Continuation of revenue growth from licensed products and manufacturing supply
- Commencement of the Anafilm pivotal trial pending FDA feedback
For full-year 2023, management raised guidance:
- Total revenues of $44 million to $48 million (up from $42 million to $46 million)
- Non-GAAP adjusted EBITDA loss of $19 million to $22 million (improved from prior $24 million to $28 million)
Management highlighted several factors that will influence results:
- Market share erosion for legacy Suboxone is expected to be modest but will be offset by licensed product growth
- R&D spending will remain focused on Anafilm pivotal trial and pipeline advancement
Takeaways
Aquestive’s quarter demonstrates a disciplined pivot to a royalty-driven model, with pipeline progress and partnership optionality now central to the equity story.
- Pipeline Execution is Paramount: Near-term FDA alignment on Anafilm and Libervant milestones will define the company’s value trajectory.
- Financial Flexibility Improved: Debt reduction, warrant resolution, and cash conservation provide breathing room for R&D execution.
- Watch for Regulatory and Partnership Catalysts: Investors should monitor trial initiation, ex-US licensing deals, and evolving market dynamics in epinephrine and CNS rescue therapies.
Conclusion
Aquestive is emerging from a period of transformation with a streamlined cost structure, robust out-licensing engine, and a pipeline approaching pivotal milestones. Execution on Anafilm and Libervant, coupled with disciplined capital management, will determine if AQST can convert its IP and clinical progress into durable shareholder value.
Industry Read-Through
Aquestive’s results underscore a broader shift in specialty pharma toward royalty and out-licensing models, as companies seek to reduce capital intensity and risk by leveraging platform technologies. Pipeline differentiation and regulatory clarity remain critical for companies targeting CNS and allergy rescue markets, where delivery innovation and unmet need drive both advocacy and reimbursement tailwinds. Competitors in drug-device and oral delivery spaces should note the accelerating prescription growth and legislative focus on access, which could expand market opportunities but also intensify competition for first-mover advantage and payer positioning.